Ensyce Biosciences Inc. (ENSC), a clinical-stage pharmaceutical company, on Thursday announced the expansion of a patent on its MPAR technology for preventing drug abuse, issued by the U.S. patent and trademark office (USPTO).
The company developed the multi-pill abuse resistance (MPAR) platform to reduce the impact of opioid exposure during an overdose. As part of the program, PF614-MPAR demonstrated provision of pain relief in clinical studies and prevented excessive opioid release with multiple doses. The technology previously received a fast-track designation from the FDA.
The patent expansion was issued in April and covers both composition-of-matter and method-of-use regarding MPAR, and protects these claims till 2042.
The company plans to advance PF614 and PF614-MPAR through late-stage clinical development to potentially reduce opioid abuse and overdose.
ENSC closed Monday at $0.32, up 13.17%. In the pre-market, shares are trading at $0.29, down 8.52%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.